Exhibits eukaryotic initiation factor 4E binding activity. Involved in lung development and response to ethanol. Localizes to eukaryotic translation initiation factor 4F complex and postsynapse. Human ortholog(s) of this gene implicated in late onset Parkinson's disease. Orthologous to human EIF4G1 (eukaryotic translation initiation factor 4 gamma 1); PARTICIPATES IN translation initiation pathway; myocarditis pathway; RNA transport pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; amphetamine; bis(2-ethylhexyl) phthalate.
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis4-hydroxyphenylsulfone] results in decreased expression of EIF4G1 mRNA more ...
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis4-hydroxyphenylsulfone] results in decreased expression of EIF4G1 mRNA
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of and results in increased oxidation of EIF4G1 mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in decreased expression of and results in increased oxidation of EIF4G1 mRNA
Glucose promotes the reaction [EIF4E protein binds to EIF4G1 protein], resveratrol inhibits the reaction [Glucose promotes the reaction [EIF4E protein binds to EIF4G1 protein]]
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of and results in increased oxidation of EIF4G1 mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in decreased expression of and results in increased oxidation of EIF4G1 mRNA
arsenite promotes the reaction [EIF4E protein binds to EIF4G1 protein], MAPK14 protein affects the reaction [arsenite promotes the reaction [EIF4E protein binds to EIF4G1 protein]]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of EIF4G1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EIF4G1 mRNA
Glucose promotes the reaction [EIF4E protein binds to EIF4G1 protein], resveratrol inhibits the reaction [Glucose promotes the reaction [EIF4E protein binds to EIF4G1 protein]]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis4-hydroxyphenylsulfone] results in decreased expression of EIF4G1 mRNA more ...
Glucose promotes the reaction [EIF4E protein binds to EIF4G1 protein], resveratrol inhibits the reaction [Glucose promotes the reaction [EIF4E protein binds to EIF4G1 protein]]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis4-hydroxyphenylsulfone] results in decreased expression of EIF4G1 mRNA more ...
2-4-morpholinyl-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of EIF4G1 protein]
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of and results in increased oxidation of EIF4G1 mRNA more ...
2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of EIF4G1 protein] more ...
[2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one co-treated with SB 203580] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of EIF4G1 protein]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin